Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Note 10 - Commitments, Contingencies and Guarantees (Details Textual)

v3.10.0.1
Note 10 - Commitments, Contingencies and Guarantees (Details Textual) - USD ($)
$ in Millions
Sep. 30, 2018
Jun. 13, 2018
CrystalGenomics [member] | Exclusive license to cg806 outside of Korea and China [member] | Development Milestones [Member]    
Statement Line Items [Line Items]    
Possible future milestone payment $ 16.0  
CrystalGenomics [member] | Exclusive license to cg806 outside of Korea and China [member] | Regulatory Milestones [Member]    
Statement Line Items [Line Items]    
Possible future milestone payment 44.0  
CrystalGenomics [member] | Exclusive license to cg806 in China [member] | Development Milestones [Member]    
Statement Line Items [Line Items]    
Possible future milestone payment   $ 6.0
CrystalGenomics [member] | Exclusive license to cg806 in China [member] | Regulatory Milestones [Member]    
Statement Line Items [Line Items]    
Possible future milestone payment   $ 20.0
Clinical development of APTO-253 and CG'806 [member]    
Statement Line Items [Line Items]    
Transaction price allocated to remaining performance obligations $ 3.5